Visiongain Publishes Ophthalmic Drugs Market Report to 2030

05 February 2021
Pharma

Visiongain has just announced the publication of its brand new report Ophthalmic Drugs Market Report to 2030: Forecasts by Indication (Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs), by Type (Prescription Drugs, OTC Drugs), by Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Ophthalmic Drugs Companies AND COVID-19 Recovery Scenarios.

Global Ophthalmic Drugs market was valued at US$XX million in 2020 and is projected to reach at a market value of US$XX million by 2030.

What new developments are taking place in the ophthalmic drug market? Which areas are going to grow at the fastest rates? Visiongain’s brand new report shows you potential revenues to 2030, assessing data, trends, opportunities and prospects there.

Includes EXCLUSIVE Covid-19 variations – not available anywhere else.

Our unique report provides tables, charts, and graphs not available anywhere else. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions.

Forecasts to 2030 and other analyses show you commercial prospects
Besides revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis), product profiles and commercial developments.

COVID-19 Impact on Ophthalmic Drugs Market

See revenue forecasts for the leading international markets
How will leading national markets perform to 2030? Our study forecasts ophthalmic drug revenues in national markets, including:

By Region

• North America
- U.S.
- Canada

• Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Poland
- Rest of Europe

• Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific

• Latin America
- Brazil
- Mexico
- Rest of Latin America

• Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of Middle East & Africa

Leading companies and potential for market growth
Overall world revenue for ophthalmic drug market will reach $XX in 2021, our work forecasts. We predict strong revenue growth through to 2030. The ageing population in many of the world's largest markets will combine with a shift towards newer and more expensive lenses which will drive sales to 2030.

Our work analyses the key companies in the market. See Visiongain’s analysis of leading ophthalmic drug companies, including these:
• Novartis
• Regeneron
• Allergan
• Roche
• Santen Pharmaceutical Co.,
• Bayer
• Pfizer
• Senju Pharmaceutical Company Ltd (Senju)
• Bausch Health Companies Inc.
• Akorn, Inc.
• Sun Pharmaceutical Industries Ltd.
• Aerie Pharmaceuticals Inc
• Biogen

A company profile gives you the following information where available:
• Historical revenues
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs? You see trends for these areas and technologies.

The R&D pipeline for ophthalmic drugs is particularly strong, with faster and more precise drugs being in demand. Others, though not revolutionary are instead increase the efficiency of current therapies.

In this report you will discover key discussions on regulatory, technical, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population.

26 January 2022

Read

Visiongain Publishes Topical Drug Delivery Market Report 2022-2032

Some of the factors driving the market growth are the increasing prevalence of skin and eye diseases, high incidences of burn incidences and the growing prevalence of diabetes.

26 January 2022

Read

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

Read

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever